Home / Alternatives / Managing complexity – A buy enters the Citadel (ASX:CGL)

Managing complexity – A buy enters the Citadel (ASX:CGL)

Alternatives

Pacific Equity Partners is looking to acquire 100% of the Citadel Group (ASX: CGL) in  a transaction worth $503 million. PEP is planning to provide funding to help Citadel expand its global footprint and to develop new products in specialist software and critical-secure information management for its customers in healthcare, defence and national security, government and tertiary education.

  • With the tagline ‘managing complexity’ and a name associated with a fortress, CGL has built a business on integrating technology into the most important functions within the healthcare and government sectors. Its ability to protect data, but also leverage this data to push forward with innovations ranging from facial capture and number plate recognition, has piqued PEP’s interest.

    The transaction will be done through a scheme of arrangement, for $5.70 a share in cash, reduced to the extent of any special dividend. The dividend is 15 cents per share (special dividend).

    The cash consideration of $5.70 a share represents a significant premium of 43.2% to the last closing price of $3.98, and 51.4% to the three-month volume-weighted average price (VWAP), of $3.76.

    The Citadel board believe the offer is compelling because:

    • 43.2% premium to the closing price of Citadel shares on ASX of $3.98 on 11 September 2020
    • 51.4% premium to the 3-month VWAP of Citadel shares of $3.76 per share
    • 66.5% premium to the VWAP of Citadel shares since Wellbeing share issuance of $3.42 per share

    Citadel Chairman, Lt-Gen (retired)Peter Leahy AC,  said: “The scheme is an attractive transaction which provides an all-cash option for Citadel shareholders. The Citadel board has unanimously concluded that the scheme represents a compelling outcome for our shareholders, customers, suppliers and staff.”

    The company has been on a strong trajectory since before COVID hit, trading as high as $9.20 in late 2018.

    Ishan Dan

    Ishan is an experienced journalist covering The Inside Investor and The Insider Adviser publications.




    Print Article

    Related
    High regulatory bar makes healthcare a solid value play: Perennial

    Idiosyncratic regulations around healthcare product marketing in Australia has led to an under-represented market, which in turn presents an opportunity for savvy investors according to Perennial Partners.

    Tahn Sharpe | 31st Oct 2024 | More
    ‘No short-term phenomenon’: Why private capital will not only survive but thrive beyond 2025

    Pessimists are still trying to shoehorn the “bubble” narrative into the private capital story, but an EY report highlights not only the rise of this burgeoning ‘alternative’ sector, but the reasons it’s likely to keep growing.

    Tahn Sharpe | 3rd Oct 2024 | More
    ‘The foundations are pretty soft’: Correlation considerations taking centre stage

    With the danger of fractured markets inflated, the need for a truly non-correlative asset is at a premium. And with the default system cleaned up, Fortlake saw an opportunity to provide investors with the ultimate diversifier.

    Tahn Sharpe | 16th Sep 2024 | More
    Popular
  • Popular posts: